載入中
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
最新資料
US$1.23
−US$0.07 · -5.38%
Cardiol Therapeutics Inc. is a clinical-stage life sciences firm dedicated to discovering and advancing anti-fibrotic and anti-inflammatory therapies for cardiovascular disease (CVD). Its leading candidate, CardiolRx, is currently undergoing a multi-national, randomized, double-blind, placebo-controlled Phase II/III study. This pivotal trial assesses CardiolRx's safety and effectiveness as a cardioprotective treatment to diminish cardiovascular and respiratory complications in hospitalized COVID-19 patients, while also investigating its potential for acute myocarditis. Furthermore, the company is developing a subcutaneous version of CardiolRx, aimed at addressing the cardiac fibrosis and inflammation linked to the onset and progression of heart failure. Cardiol Therapeutics Inc. was established in 2017 and operates from its headquarters in Oakville, Canada.
前收盤價
US$1.23
−US$0.07 · -5.38%
盤中時間採用ET。市場資料可能有所延遲。
Cardiol Therapeutics Inc. is a clinical-stage life sciences firm dedicated to discovering and advancing anti-fibrotic and anti-inflammatory therapies for cardiovascular disease (CVD). Its leading candidate, CardiolRx, is currently undergoing a multi-national, randomized, double-blind, placebo-controlled Phase II/III study. This pivotal trial assesses CardiolRx's safety and effectiveness as a cardioprotective treatment to diminish cardiovascular and respiratory complications in hospitalized COVID-19 patients, while also investigating its potential for acute myocarditis. Furthermore, the company is developing a subcutaneous version of CardiolRx, aimed at addressing the cardiac fibrosis and inflammation linked to the onset and progression of heart failure. Cardiol Therapeutics Inc. was established in 2017 and operates from its headquarters in Oakville, Canada.
日內區間
目前US$1.23
52週區間
目前US$1.23
盤中時間採用ET。市場資料可能有所延遲。
Cardiol Therapeutics Inc. is a clinical-stage life sciences firm dedicated to discovering and advancing anti-fibrotic and anti-inflammatory therapies for cardiovascular disease (CVD). Its leading candidate, CardiolRx, is currently undergoing a multi-national, randomized, double-blind, placebo-controlled Phase II/III study. This pivotal trial assesses CardiolRx's safety and effectiveness as a cardioprotective treatment to diminish cardiovascular and respiratory complications in hospitalized COVID-19 patients, while also investigating its potential for acute myocarditis. Furthermore, the company is developing a subcutaneous version of CardiolRx, aimed at addressing the cardiac fibrosis and inflammation linked to the onset and progression of heart failure. Cardiol Therapeutics Inc. was established in 2017 and operates from its headquarters in Oakville, Canada.
日內區間
目前US$1.23
52週區間
目前US$1.23
營業利益
淨利
| 項目（CAD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | — | — | — | — | 6.23萬 CAD |
| 銷貨成本 | — | — | 18.74萬 CAD | 16.22萬 CAD | 17.43萬 CAD |
| 毛利 | — | — | −18.74萬 CAD | −16.22萬 CAD | −11.2萬 CAD |
| 研究與開發 | 1401.85萬 CAD | 1401.21萬 CAD | 1073.22萬 CAD | 1398.83萬 CAD | 859.42萬 CAD |
| 銷售、一般及管理費用 | 2019.59萬 CAD | 2589.14萬 CAD | 1155.36萬 CAD | 1634.29萬 CAD | 2186.22萬 CAD |
| 營業費用 | 3431.63萬 CAD | 4027.67萬 CAD | 2228.58萬 CAD | 3033.13萬 CAD | 3045.64萬 CAD |
| 利息收入 | 72.64萬 CAD | 119.33萬 CAD | 203.85萬 CAD | 123.76萬 CAD | 10.6萬 CAD |
| 折舊和攤銷 | 10.2萬 CAD | 37.31萬 CAD | 24.84萬 CAD | 21.99萬 CAD | 22.04萬 CAD |
| 營業利益 | −3431.63萬 CAD | −4027.67萬 CAD | −2247.32萬 CAD | −3049.35萬 CAD | −3056.84萬 CAD |
| 淨利 | −3381.89萬 CAD | −3667.73萬 CAD | −2122.28萬 CAD | −2281.75萬 CAD | −2501.32萬 CAD |
公司資料更新於 2026年10月11日。
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$8.00
上漲空間 550.41%報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
